Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade was showed to induce a larger number of antibody responses in the clinical responders than non-responders in patients with prostate cancer [6]. The gene discussed is CTLA4; the disease is Familial prostate cancer.